Headaches, Dizziness, and Blood Pressure on a GLP-1 Microdose: Why the First Weeks Feel Lightheaded
Day nine of a protocol and there is a dull ache behind the eyes by mid-afternoon, a brief grey-out on standing from the sofa, and a vague sense that something is off. The medication is involved, but mostly at one remove. Here is what the trials measured, what the drug does to fluid, caffeine, and blood pressure, and which symptoms belong on a prescriber's desk.
14% vs 10%
HEADACHE ON SEMAGLUTIDE 2.4 MG VERSUS PLACEBO IN THE WEGOVY PRESCRIBING INFORMATION
8% vs 4%
DIZZINESS ON SEMAGLUTIDE 2.4 MG VERSUS PLACEBO ACROSS THE STEP TRIALS
5 mmHg
PLACEBO-ADJUSTED FALL IN SYSTOLIC BLOOD PRESSURE WITH SEMAGLUTIDE 2.4 MG AT 68 WEEKS IN STEP 1
A woman in her forties starts a low weekly dose of semaglutide with no side effects to speak of for the first five days. Then the headaches begin: not severe, not sharp, a steady pressure across the forehead that shows up around three in the afternoon and lingers until bed. On day eleven she stands up quickly in the kitchen and the room dims for a second. She has not felt nauseated once. She has, without noticing, gone from three coffees a day to one, from two and a half litres of fluid to barely one, and from three meals to one and a half.
Her experience is the ordinary one. Headache and dizziness are listed among the most common adverse reactions in the prescribing information for every GLP-1 receptor agonist, and neither is well explained by anything the drug does to the brain directly. They are explained by what the drug does to intake. GLP-1 receptor agonists suppress thirst along with appetite, they remove the desire for coffee as efficiently as the desire for a second helping, they reduce the sodium and glucose that arrive with food, and they lower blood pressure through weight loss and through the kidney. A body that is drier, more caffeine-deprived, and running a lower blood pressure than it was two weeks earlier will produce exactly the symptoms in the label.
This article covers what the trials and prescribing information report about headache, dizziness, and hypotension, the four mechanisms that produce most of it, the blood pressure data from the outcome trials and the ambulatory monitoring substudy, why the same drug class is now being tested as a migraine preventive, what a microdose changes, and a table that separates the symptoms that respond to water and a morning coffee from the ones that need a clinician.
Key takeaways
- •The Wegovy prescribing information reports headache in 14 percent of people on semaglutide 2.4 mg versus 10 percent on placebo, dizziness in 8 versus 4 percent, and hypotension-related reactions in 1.3 versus 0.4 percent, and these reactions cluster in the first weeks and during dose increases.
- •Most GLP-1 headaches are secondary: reduced fluid intake because thirst is suppressed alongside appetite, caffeine withdrawal because coffee intake falls, and under-eating that lowers glucose and sodium, each of which produces a headache on its own and each of which has a specific fix.
- •GLP-1 medications lower systolic blood pressure by about 5 mmHg with semaglutide 2.4 mg in STEP 1 and 6 to 7 mmHg with tirzepatide in SURMOUNT-1, and a 24-hour ambulatory substudy published in 2024 found reductions of 7.4 to 10.6 mmHg across tirzepatide doses at 36 weeks.
- •Blood pressure falls through weight loss, through increased sodium excretion by the kidney documented by Gutzwiller in 2004, and through atrial natriuretic peptide release shown by Kim and colleagues in 2013, and the combined effect can make a pre-existing antihypertensive dose too high, which is the most common cause of orthostatic dizziness on a protocol.
- •The drug class is not intrinsically headache-provoking: a 2024 pilot study of liraglutide in people with obesity and migraine reported monthly headache days falling from about 20 to 9 over 12 weeks, and exenatide lowered intracranial pressure in a randomised trial of idiopathic intracranial hypertension in 2023.
- •A headache that persists after three days of a fluid target and stable caffeine, dizziness that causes a near-faint, shakiness in anyone on insulin or a sulfonylurea, or a sudden severe headache with vision change or weakness should go to a clinician rather than be managed with more water.
How common are headaches and dizziness on a GLP-1 medication?
Headache and dizziness are common but only modestly more common than on placebo. The Wegovy prescribing information, which pools the STEP trials of semaglutide 2.4 mg, lists headache at 14 percent versus 10 percent on placebo, dizziness at 8 percent versus 4 percent, and fatigue at 11 percent versus 5 percent. Adverse reactions related to hypotension, a group that includes orthostatic hypotension and decreased blood pressure, were reported in 1.3 percent of semaglutide participants versus 0.4 percent on placebo. The Zepbound label for tirzepatide reports a similar pattern with dizziness and fatigue both more frequent than placebo and hypotension events reported in a small minority. The Saxenda label for liraglutide 3.0 mg lists headache at 14 percent versus 9 percent.
Two features of the data matter for interpretation. First, the background rate is high. One in ten people on placebo reported a headache during a 68-week trial, because headaches are common, and the drug adds roughly four percentage points on top. Second, the trials measured whether a headache was reported at all, not when. Clinical experience and the discontinuation data both point to the first month and the weeks after each dose increase as the period when headache and dizziness cluster, which is the same window in which fluid and food intake drop most steeply. A headache that first appears at month six is less likely to be the medication than one that appears in week two.
Neither headache nor dizziness appears in the warnings and precautions section of any GLP-1 label as a direct drug effect. Hypotension does, in the context of concomitant antihypertensive therapy, and hypoglycaemia does, in the context of insulin and sulfonylureas. That placement is a useful map: the label treats headache and dizziness as symptoms, and treats low blood pressure and low blood sugar as the conditions worth watching for underneath them.
Selected adverse reactions, semaglutide 2.4 mg versus placebo, percent of participants
From the Wegovy prescribing information, pooled STEP trials, reactions reported in at least 2 percent of participants and more often than placebo. Hypotension-related reactions are drawn from the label's hypotension section.
- Semaglutide 2.4 mg
- Placebo
The drug roughly doubles the rate of dizziness and fatigue and adds four points to headache. Hypotension events are rare in both arms but three times more common on the drug.
Why does a GLP-1 microdose cause headaches?
A GLP-1 medication causes headaches mainly by changing what a person drinks, eats, and consumes in caffeine, not by acting on pain pathways in the brain. The first and largest contributor is fluid. GLP-1 receptor agonists reduce thirst as well as hunger, an effect documented in the same hypothalamic circuits that govern appetite, and in an ordinary diet most water arrives with meals, in soup, fruit, coffee, and the glass poured at dinner. When meals shrink or disappear, fluid intake falls with them and thirst does not sound the alarm. A drop of 20 to 30 percent in daily water intake over a week is enough to produce a mild dehydration headache in most adults, and it produces the concentrated urine, dry mouth, and afternoon fatigue that usually accompany it.
The second contributor is caffeine. Coffee is one of the first things people stop wanting on a GLP-1 medication, partly because the drug blunts reward-seeking generally and partly because a hot drink on an empty, slower-emptying stomach is less appealing. A regular drinker of three cups a day who drops to one has cut roughly 200 mg of caffeine overnight, and caffeine withdrawal headache reliably appears 12 to 24 hours after the last usual dose, peaks at one to two days, and can last up to nine days according to the diagnostic criteria for the condition. It is typically diffuse, throbbing, worse with exertion, and improves within an hour of a cup, which is the easiest confirmation available.
The third contributor is intake itself. A person eating a third of their previous calories takes in a third of the previous sodium, and a modest fall in blood sodium combined with lower blood volume produces headache and lightheadedness. Blood glucose sits lower between meals, and while true hypoglycaemia is uncommon on a GLP-1 medication in people who do not take insulin or a sulfonylurea, the trough between a small lunch and a late dinner is enough to make some people foggy and headachy. Sleep disruption from a changed routine, and the drug's small blood pressure lowering effect described in the next section, fill out the picture.
Illustrative first-quarter pattern: fluid intake and headache days on a new GLP-1 protocol
Conceptual curves. Fluid intake is shown as a percentage of the pre-protocol baseline; headache days are an illustrative percentage of days with any headache. Drawn to show the typical shape reported in practice, where the trough in fluid intake in weeks one to three coincides with the peak in headaches, and both recover as a fluid routine is established. Not measured data.
- Fluid intake, % of baseline
- Days with headache, %
The two lines are mirror images. Week two is where fluid bottoms out and headaches peak, and both settle by week eight once drinking becomes a scheduled habit rather than a thirst response.
Illustrative attribution of first-month headaches on a GLP-1 protocol, percent
An approximate breakdown based on the mechanisms discussed and clinical experience, not a measured distribution. The purpose is to show that the large majority of early headaches trace to intake rather than to the drug's action on the nervous system.
Three of the five bars are fixed with a water bottle, a consistent coffee, and a calorie floor. The blood pressure bar is the one that needs a prescriber.
Does a GLP-1 medication lower blood pressure?
Yes, and by enough to matter. In STEP 1, reported by Wilding and colleagues in the New England Journal of Medicine in 2021, semaglutide 2.4 mg lowered systolic blood pressure by 6.2 mmHg from baseline at 68 weeks compared with 1.1 mmHg on placebo, a placebo-adjusted difference of about 5 mmHg. In SURMOUNT-1, Jastreboff and colleagues reported in 2022 that tirzepatide lowered systolic pressure by roughly 6 to 7 mmHg more than placebo across the 5, 10, and 15 mg doses at 72 weeks. In the SELECT cardiovascular outcome trial published in 2023, semaglutide 2.4 mg lowered systolic pressure by about 3.8 mmHg relative to placebo in more than 17,000 people with established cardiovascular disease, and that trial found 20 percent fewer major cardiovascular events over a mean follow-up of nearly three and a half years.
Clinic readings taken once every few months can miss the size of the effect. De Lemos and colleagues published a 24-hour ambulatory blood pressure substudy of SURMOUNT-1 in Hypertension in 2024, in which around 500 participants wore a monitor for a full day at baseline and at 36 weeks. Tirzepatide reduced 24-hour systolic pressure by 7.4 mmHg at 5 mg, 10.6 mmHg at 10 mg, and 8.0 mmHg at 15 mg relative to placebo, with the effect present across the day and overnight. For scale, the reduction from a standard dose of a single antihypertensive drug is often quoted at around 8 to 10 mmHg systolic, so a full-dose GLP-1 medication delivers roughly the effect of one blood pressure tablet on top of whatever the person is already taking.
That arithmetic is the most important sentence in this article for anyone already on an antihypertensive. A dose of amlodipine, lisinopril, or a thiazide diuretic that was correct for a person at 95 kg with a normal salt intake can be too much for the same person at 82 kg eating half the sodium, and the first sign is usually not a clinic reading but a grey-out on standing in the morning. The Wegovy and Zepbound prescribing information both note that patients on antihypertensive therapy should be monitored, and in the outcome trials a meaningful share of participants had their blood pressure medications reduced during follow-up.
Placebo-adjusted reduction in systolic blood pressure by trial, mmHg
Approximate values derived from the primary publications: SELECT at 104 weeks, STEP 1 and SURMOUNT-1 at 68 and 72 weeks. Clinic measurements. Values rounded to one decimal place and drawn from reported treatment differences.
Every bar sits to the left of zero. The size scales roughly with the amount of weight lost in each trial, which is the largest single mechanism.
24-hour ambulatory systolic blood pressure change versus placebo, tirzepatide at 36 weeks, mmHg
From the SURMOUNT-1 ambulatory blood pressure monitoring substudy, de Lemos and colleagues, Hypertension 2024. Roughly 500 participants wore a 24-hour monitor at baseline and week 36. Dose-response is not linear, which the authors attributed to sample size within each arm.
Around the clock, the reduction is larger than the clinic numbers suggest. Ten mmHg is what a single antihypertensive drug is expected to deliver.
Why do GLP-1 medications lower blood pressure?
Weight loss is the largest reason, and two drug-specific mechanisms add to it. Losing 10 to 15 percent of body weight lowers blood volume, reduces the cardiac output needed to perfuse a smaller body, improves insulin sensitivity, and dials down the sympathetic nervous system overactivity that accompanies excess adiposity. Every weight loss method that achieves that magnitude, from bariatric surgery to a supervised very low calorie diet, lowers blood pressure by a comparable amount, so a good share of the GLP-1 effect is simply weight.
The kidney is the first drug-specific route. Gutzwiller and colleagues reported in the Journal of Clinical Endocrinology and Metabolism in 2004 that infusing GLP-1 into obese men with insulin resistance increased urinary sodium excretion and reduced glomerular hyperfiltration, an effect independent of any weight change because it was measured over hours. A drug that makes the kidney excrete more sodium behaves, in that respect, like a mild diuretic, and a mild diuretic lowers blood pressure and blood volume. Combine that with a diet that now contains a third of the previous sodium and the volume effect becomes noticeable, which is why diuretics are the antihypertensives most often reduced first on a GLP-1 protocol.
The heart is the second. Kim and colleagues showed in Nature Medicine in 2013 that activating GLP-1 receptors in the atria of mice triggered secretion of atrial natriuretic peptide, a hormone that relaxes blood vessel walls and promotes sodium loss, and that the blood pressure lowering effect of liraglutide in those animals depended on it. Whether the same pathway operates at the same magnitude in people is still debated, and human studies have produced mixed results, but it fits the observation that blood pressure falls within the first weeks of treatment, before much weight has come off. That early fall, arriving at the same time as the drop in fluid intake, is what produces the lightheaded fortnight that so many people describe.
Is the GLP-1 drug class actually being studied to prevent headaches?
Yes, which is the strongest argument that the headaches of the first weeks are not a direct drug effect. Braca and colleagues published a pilot study in the journal Headache in 2024 in which 31 adults with obesity and high-frequency or chronic migraine, who had failed conventional preventives, took liraglutide for 12 weeks. Mean monthly headache days fell from about 20 to about 9, and the improvement was not correlated with the small amount of weight lost, which suggested a mechanism other than weight. The authors' hypothesis was intracranial pressure: GLP-1 receptors are present in the choroid plexus, where cerebrospinal fluid is produced, and lowering cerebrospinal fluid secretion would reduce the pressure that appears to drive migraine in a subset of people with obesity.
That hypothesis rests on an earlier randomised trial. Mitchell and colleagues reported in Brain in 2023 that exenatide, an older GLP-1 receptor agonist, reduced intracranial pressure measured directly by an implanted sensor in women with idiopathic intracranial hypertension, a condition of raised cerebrospinal fluid pressure that produces daily headache and threatens vision. The reduction was present within hours of the first dose and persisted at 12 weeks, and monthly headache days fell alongside it. Larger trials in both conditions are under way. None of that is a reason to take a GLP-1 medication for headaches today, and no GLP-1 receptor agonist is approved for any headache disorder, but it does mean the drug's action in the brain is, if anything, the opposite of headache-provoking.
Monthly headache days in a pilot study of liraglutide for migraine in people with obesity
Approximate means from Braca and colleagues, Headache 2024, 31 participants, open-label, 12 weeks. A pilot study without a placebo group; the values are shown for the size of the effect, not as proof of efficacy.
A halving of headache days in a treatment-resistant group, with weight loss of only a few kilograms. The mechanism appears to be pressure, not pounds.
Are headaches and dizziness milder on a GLP-1 microdose?
Milder, usually, but not absent, and the reason is instructive. The gastrointestinal side effects of GLP-1 medications track dose closely, which is why every label has an escalation schedule that starts at a fraction of the maintenance dose. Headache and dizziness track dose more loosely, because their main drivers are downstream of appetite suppression rather than of the drug concentration itself. Appetite suppression begins at low doses, and the moment a person eats and drinks less, fluid intake, caffeine intake, and sodium intake all fall. A microdose produces a gentler version of that, so the drop in fluid and coffee is smaller and the headaches are correspondingly milder, but someone who was drinking most of their water at meals will still notice the difference in week two.
The blood pressure effect scales more cleanly with dose and with weight loss, and a microdose produces less of both. Someone on a quarter to a third of a standard maintenance dose should expect a systolic reduction at the low end of the trial ranges, and a slower one, because the weight-driven component accumulates over months. That is good news for people not on antihypertensives, who will get a small benefit, and it is still worth a conversation for people who are, because even 3 mmHg on top of a well-titrated regimen can tip someone into morning lightheadedness.
No trial has reported adverse reaction rates at true microdose levels, and the honest position is extrapolation from the dose-escalation phases of the standard trials, in which the starting doses produced fewer events than the maintenance doses. The practical advantage of a microdose is that the fixes are proportionally easier: a scheduled two litres of fluid, one consistent morning coffee, and a floor under daily calories cover the great majority of early headaches, and the remaining lightheadedness is usually a blood pressure medication that now needs revisiting.
Which headaches and dizzy spells need a prescriber?
Most early headaches on a GLP-1 protocol respond to fluid, caffeine, and food within days, and a headache that does not respond to those three within three days is the one to report. Dizziness on standing in someone taking a blood pressure medication needs a medication review rather than more water. Shakiness or sweating in someone taking insulin or a sulfonylurea needs a glucose check and a same-day call. A sudden severe headache, or any headache with vision change, weakness, numbness, confusion, or fainting, needs emergency assessment and should never be attributed to the medication first.
The table below matches the common patterns to what most often lies behind them and what to do next. The useful principle across all of them is that a hydration headache, a caffeine headache, and a low-intake headache each resolve quickly when the specific cause is addressed, and their resolution is itself the confirmation. A headache that survives all three corrections has a different cause.
| Pattern | Most likely cause | Practical approach |
|---|---|---|
| Dull, whole-head ache in the first two or three weeks, worse in the afternoon, with dark urine, dry mouth, or fewer trips to the bathroom | Low fluid intake, because the medication blunts thirst alongside appetite | Set a fluid target of two to three litres a day and hit it on a schedule rather than waiting to feel thirsty. Add electrolytes if food intake has dropped sharply. Most hydration headaches lift within a day or two of meeting the target, which is also the diagnostic test. |
| Headache starting 12 to 24 hours after coffee intake dropped, with heavy fatigue and poor concentration, easing after a cup | Caffeine withdrawal, which arrives when a GLP-1 medication quietly halves the number of coffees a person wants | Taper caffeine over one to two weeks rather than letting it fall off a cliff. A smaller morning coffee kept at a consistent time prevents the withdrawal headache without adding back the afternoon dose that disturbs sleep. |
| Lightheaded or grey-out on standing up, especially in the morning or after a hot shower, in someone taking a blood pressure medication | Blood pressure that has fallen with weight loss and lower salt intake, so the antihypertensive dose now overshoots | Check blood pressure seated and then standing at home and take the log to the prescriber. Antihypertensive doses are often reduced as weight comes off. Do not stop a blood pressure medication without that conversation; stand up in stages in the meantime. |
| Shaky, sweaty, anxious, or foggy with hunger, relieved within minutes of eating, in someone who also takes insulin or a sulfonylurea | Hypoglycaemia, which the prescribing information warns about when a GLP-1 agent is combined with those medications | Confirm with a fingerstick glucose reading if a meter is available. The insulin or sulfonylurea dose usually needs adjusting when a GLP-1 medication is added, and the prescriber should be told the same day. In people not taking those medications, true hypoglycaemia is uncommon and the more likely explanation is simply too few calories. |
| Sudden severe headache, the worst ever, or a headache with vision change, weakness, numbness, confusion, fever with stiff neck, or fainting | A symptom pattern that needs urgent medical assessment regardless of medication | These are not medication-adjustment questions. Seek emergency care. Nothing in the GLP-1 literature explains a thunderclap headache or a focal neurological symptom, and the medication should not be assumed to be the cause. |
2 to 3 L
Daily fluid target for most adults on a GLP-1 protocol, taken on a schedule because thirst can no longer be trusted to prompt it
12 to 24 h
Typical onset of caffeine withdrawal headache after a sharp drop in coffee intake, with symptoms lasting up to nine days
3 days
Reasonable trial of fluid, stable caffeine, and a calorie floor before a persistent headache is reported to the prescriber
The headache is real. The cause is usually in the kitchen.
A GLP-1 receptor agonist turns down thirst, appetite, and the desire for coffee together, and it lowers blood pressure through the kidney, the heart, and the scale. The label's 14 percent headache rate and 8 percent dizziness rate are what those four changes look like when they land on a body in the same fortnight. Almost none of it is the drug acting on the brain; the drug class is, in fact, being tested to prevent headaches in people with obesity. What that means in practice is that the first three weeks of a protocol deserve a water bottle on the desk, one coffee kept at the same time each morning, a floor under daily calories, and, for anyone taking a blood pressure tablet, a week of seated and standing readings to hand to the prescriber. A microdose makes each of those adjustments smaller. It does not make them optional.
"The medication took away the thirst, the coffee, and five points of blood pressure in the same week. The headache is the body noticing all three."
Frequently asked questions
Do GLP-1 medications cause headaches?
Headache is listed as a common adverse reaction in the Wegovy prescribing information, reported by 14 percent of people taking semaglutide 2.4 mg compared with 10 percent on placebo across the STEP trials. The 4 percentage point difference is modest, and the pattern in practice is that headaches cluster in the first weeks of a protocol and during dose increases. Most are secondary to what the medication does to fluid intake, caffeine intake, and food intake rather than to any direct action of GLP-1 on the brain. Liraglutide is currently being studied as a migraine preventive in people with obesity, which suggests the drug class itself is not intrinsically headache-provoking.
Why does a GLP-1 microdose cause headaches in the first few weeks?
The most common cause is reduced fluid intake. GLP-1 receptor agonists suppress thirst along with appetite, and most fluid in an ordinary diet arrives with meals, so total water intake can fall by a fifth or more within days of starting. Caffeine withdrawal is the second cause, because coffee is one of the first things people stop wanting, and a drop from three cups to one produces a withdrawal headache within 12 to 24 hours. Under-eating adds a third contributor through low blood glucose and low sodium. The dizziness that often accompanies these headaches usually comes from the same reduced blood volume. Each of these causes responds to a specific fix within days.
Does semaglutide or tirzepatide lower blood pressure?
Yes, and by a clinically meaningful amount at standard doses. In the STEP 1 trial, semaglutide 2.4 mg lowered systolic blood pressure by 6.2 mmHg compared with 1.1 mmHg on placebo, a placebo-adjusted reduction of about 5 mmHg. In SURMOUNT-1, tirzepatide lowered systolic pressure by roughly 6 to 7 mmHg more than placebo across the three doses. A 24-hour ambulatory monitoring substudy of SURMOUNT-1 published in Hypertension in 2024 found reductions of 7.4, 10.6, and 8.0 mmHg at 5, 10, and 15 mg after 36 weeks. In the SELECT outcome trial, semaglutide reduced systolic pressure by about 3.8 mmHg relative to placebo over more than two years.
Why do GLP-1 medications lower blood pressure?
Weight loss is the largest contributor, since losing 10 to 15 percent of body weight reduces blood volume, cardiac workload, and sympathetic tone. Two drug-specific mechanisms add to it. GLP-1 increases sodium excretion by the kidney: Gutzwiller and colleagues showed in 2004 that a GLP-1 infusion raised urinary sodium excretion in obese men. Kim and colleagues reported in Nature Medicine in 2013 that GLP-1 receptor activation in the heart triggers release of atrial natriuretic peptide, a hormone that relaxes blood vessels and promotes sodium loss, in mice. Lower food intake also means lower salt intake. The blood pressure fall is one of the reasons the SELECT trial found 20 percent fewer major cardiovascular events despite a small rise in heart rate.
Can a GLP-1 medication cause dizziness or low blood pressure?
Dizziness was reported by 8 percent of people on semaglutide 2.4 mg versus 4 percent on placebo in the Wegovy prescribing information, and adverse reactions related to hypotension, including orthostatic hypotension, were reported in 1.3 percent versus 0.4 percent. Most dizziness on a GLP-1 protocol is orthostatic: a brief lightheadedness on standing caused by lower blood volume from reduced fluid intake, layered on top of the drug's blood pressure lowering effect. It is more common in people already taking an antihypertensive, whose medication dose was set for a heavier body with a higher salt intake. The Wegovy and Zepbound labels both note that patients on antihypertensive medication should be monitored.
Should blood pressure medication be reduced on a GLP-1 protocol?
Often, yes, but only through the prescriber. As weight comes off and salt intake falls, a dose of lisinopril, amlodipine, or a diuretic that was correct at the start of a protocol can push blood pressure lower than intended, producing dizziness on standing, fatigue, and occasionally near-fainting. A useful approach is to take seated and standing home readings for a week and bring the log to the prescriber, who can decide whether to reduce or stop one agent. Diuretics are usually the first candidates for reduction because they compound the volume loss the GLP-1 medication already causes. Stopping an antihypertensive without that conversation risks a rebound.
Are headaches and dizziness less common on a GLP-1 microdose than on a full dose?
Probably, although no trial has reported adverse reaction rates at true microdose levels. Across the semaglutide programme, gastrointestinal side effects clearly rise with dose, which is why the label's escalation schedule exists. Headache and dizziness track dose more loosely because their main drivers, reduced fluid intake and reduced caffeine intake, appear even at low doses once appetite suppression begins. A microdose produces gentler appetite suppression, so the drop in fluid and coffee is smaller and the headaches are correspondingly milder, but they are not absent. The practical advantage of a microdose is that the fixes are easier: two litres of water and a consistent morning coffee are enough for most people.
When should a headache or dizziness on a GLP-1 medication be reported to a clinician?
A headache that persists after three days of meeting a fluid target and keeping caffeine stable, a headache that is severe or unusual for the person, or dizziness that produces a near-faint or a fall should be reported promptly. Anyone taking insulin or a sulfonylurea who feels shaky, sweaty, or foggy should check glucose and contact the prescriber the same day, because those combinations raise hypoglycaemia risk according to the prescribing information. Anyone on an antihypertensive with repeated lightheadedness on standing needs a medication review. A sudden severe headache, vision change, weakness, numbness, confusion, or fainting requires emergency assessment and should never be attributed to the medication first.
Clinical references
- Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information, adverse reactions and warnings and precautions, hypotension and hypoglycemia. US Food and Drug Administration; 2021, with subsequent revisions.
- Eli Lilly. Zepbound (tirzepatide) injection: prescribing information, adverse reactions and warnings and precautions. US Food and Drug Administration; 2023, with subsequent revisions.
- Novo Nordisk. Saxenda (liraglutide) injection 3 mg: prescribing information, adverse reactions. US Food and Drug Administration; 2014, with subsequent revisions.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
- de Lemos JA, Linetzky B, le Roux CW, et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index of 27 kg/m2 or more: SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension. 2024;81(4):e41-e43.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389(24):2221-2232.
- Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. Journal of Clinical Endocrinology and Metabolism. 2004;89(6):3055-3061.
- Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nature Medicine. 2013;19(5):567-575.
- Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Research and Clinical Practice. 2015;110(1):26-37.
- Braca S, Russo C, Miele A, et al. Liraglutide for migraine prevention in patients with obesity: a prospective pilot study. Headache. 2024, published online ahead of print.
- Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-1830.
- Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition, section 8.3.1, caffeine-withdrawal headache. Cephalalgia. 2018;38(1):1-211.
- Law M, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials. BMJ. 2009;338:b1665.
- Armstrong LE, Ganio MS, Casa DJ, et al. Mild dehydration affects mood in healthy young women. Journal of Nutrition. 2012;142(2):382-388.
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and is not a substitute for the prescriber or clinician responsible for your care. Nothing here describes a treatment for headache, migraine, idiopathic intracranial hypertension, hypertension, hypotension, hypoglycaemia, obesity, type 2 diabetes, or any other condition, and no GLP-1 receptor agonist is approved for any headache disorder or as a blood pressure medication. GLP-1 microdosing is an off label approach, no published trial has reported adverse reaction rates at microdose levels, and several charts in this article contain illustrative, conceptual, or approximated values, labelled as such, which should not be read as measured results or as targets. Do not start, stop, or change the dose of any GLP-1 medication, antihypertensive, diuretic, insulin, sulfonylurea, or any other prescription on the basis of this article. A sudden severe headache, a headache with vision change, weakness, numbness, confusion, fever with a stiff neck, or fainting requires emergency medical attention. Anyone taking blood pressure medication, insulin, or a sulfonylurea should discuss monitoring and dose adjustment with their prescriber before starting any GLP-1 protocol.